Cost-Effectiveness Analysis of Biologic Therapies for Treatment of Psoriatic Arthritis

Abstract

the Health Assessment Questionnaire (HAQ) score, utility, and the effect of treatment on HAQ had large impacts on the iNMB. For example, models that use a latent class growth model to simulate HAQ progression for patients using cDMARDs were predicted to increase the iNMB by around $45,000 relative to models that assumed a linear rate of progression. Standardized input parameters with the largest coefficients in absolute value included the extent to which the HAQ score rebounded after treatment failure and the impact of changes in the HAQ score on mortality. ConClusions: Cost-effectiveness estimates for rheumatoid arthritis vary due to both parameter and structural uncertainty. New studies are needed to improve the quality of parameter estimates; consensus-driven approaches such as Delphi panels can help determine appropriate model structures. Research should prioritize the most sensitive model parameters and debates should focus on the structural assumptions most likely to influence results.